Anti-SARS-CoV-2 and anti-cytokine storm neutralizing antibody therapies against COVID-19: Update, challenges, and perspectives

dc.creatorBatista, Cassiano Martin
dc.creatorFoti, Leonardo
dc.date2021-11-12T17:08:03Z
dc.date2021-11-12T17:08:03Z
dc.date2021
dc.date.accessioned2023-09-26T22:23:56Z
dc.date.available2023-09-26T22:23:56Z
dc.identifierBATISTA, Cassiano Martin. et al. Anti-SARS-CoV-2 and anti-cytokine storm neutralizing antibody therapies against COVID-19: Update, challenges, and perspectives. Stem Cells International. v.99, n. 108036, p. 1–10, 2021.
dc.identifier1567-5769
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/49819
dc.identifier10.1016/j.intimp.2021.108036
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8878745
dc.descriptionCoronavirus disease 2019 (COVID-19) has been declared by the World Health Organization (WHO) as a pandemic since March 2020. This disease is caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2). The only available tools to avoid contamination and transmission of this virus are physical distancing, the use of N95 and surgical masks, and hand hygiene. Vaccines are another essential tool to reduce the impact of the pandemic, though these present challenges in terms of production and logistics, particularly in underdeveloped and developing countries. One of the critical early research findings is the interaction of the spike virus protein with the angiotensin-converting enzyme 2 (ACE2) human receptor. Developing strategies to block this interaction has therefore been identified as a way to treat this infection. Neutralizing antibodies (nAbs) have emerged as a therapeutic approach since the pandemic started. Infected patients may be asymptomatic or present with mild symptoms, and others may evolve to moderate or severe disease, leading to death. An immunological phenomenon known as cytokine storm has been observed in patients with severe disease characterized by a proinflammatory cytokine cascade response that leads to lung injury. Thus, some treatment strategies focus on anti-cytokine storm nAbs. This review summarizes the latest advances in research and clinical trials, challenges, and perspectives on antibody-based treatments (ABT) as therapies against COVID-19.
dc.formatapplication/pdf
dc.languagepor
dc.publisherElsevier
dc.rightsopen access
dc.subjectSARS-CoV-2
dc.subjectCOVID-19
dc.subjectSPIKE
dc.subjectImunoterapia Passiva
dc.subjectTempestade de Citocinas
dc.subjectSpike Glycoprotein, Coronavirus
dc.subjectImmunization, Passive
dc.subjectAntibodies, Neutralizing
dc.subjectCytokine Release Syndrome
dc.subjectGlicoproteína de la Espiga del Coronavirus
dc.subjectInmunización Pasiva
dc.subjectAnticuerpos Neutralizantes
dc.subjectSíndrome de Liberación de Citoquinas
dc.subjectGlycoprotéine de spicule des coronavirus
dc.subjectImmunisation passive
dc.subjectAnticorps neutralisants
dc.subjectGlicoproteína da Espícula de Coronavírus
dc.subjectImunização Passiva
dc.subjectAnticorpos Neutralizantes
dc.subjectSíndrome da Liberação de Citocina
dc.titleAnti-SARS-CoV-2 and anti-cytokine storm neutralizing antibody therapies against COVID-19: Update, challenges, and perspectives
dc.typeArticle


Este ítem pertenece a la siguiente institución